Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.53 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11934338 | 0.91 | MTNR1B (0.52) | CYP3A4CYP2D6CYP2C19MTNR1BGRIN2C | |
| SCHEMBL11929928 | 0.89 | GHSR (0.54) | CYP3A4CYP2D6CYP2C19MTNR1BGRIN2C | |
| SCHEMBL14959565 | 0.83 | OPRD1 (0.49) | CYP3A4CYP2D6CYP2C19MTNR1BMTNR1A | |
| SCHEMBL14959566 | 0.80 | CYP2C19 (0.53) | CYP3A4CYP2D6CYP2C19MTNR1BGRIN2C | |
| SCHEMBL9529417 | 0.80 | OPRK1 (0.64) | MTNR1BGRIN2C | |
| Hydrochloric Acid SCHEMBL9530248 | 0.79 | OPRK1 (0.62) | MTNR1BGRIN2C | |
| SCHEMBL31739177 | 0.77 | GHSR (0.45) | MTNR1BALDH1A1 | |
| SCHEMBL4674938 | 0.76 | CA1 (0.53) | CYP3A4CYP2D6CYP2C19MTNR1BKDM4E | |
| SCHEMBL14959494 | 0.73 | ACE (0.41) | MTNR1BMTNR1AKDM4EALDH1A1 | |
| SCHEMBL11934342 | 0.72 | OPRD1 (0.51) | MTNR1BKDM4EALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2013-06-13 | — | — | US | disclosed |
| US-8445527-B2 | Organic compounds and their uses | NOVARTIS AG (CH) | 2013-05-21 | — | — | US | disclosed |
| WO-2007133865-A2 | HCV/HIV INHIBITORS AN THEIR USES | NOVARTIS AG (CH) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130149281-A1 | ORGANIC COMPOUNDS AND THEIR USES | OAT, HAVCR2, CPT1A | CYP3A4 68/4885CYP2D6 114/4885CYP2C19 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.